Humanized KS-IL-2 (HuKs-IL2; EMD 273066) is an immunocytokine with specific affinity for EpCAM fused at the Fc end to two IL-2 molecules (55), and it has been investigated in combination with cyclophosphamide in a Phase I/II trial of participants with recurrent EpCAM+ ovarian cancer, prostate cancer, colorectal cancer (CRC) or non-small cell lung cancers (NSCLC) (NCT00132522) (56). Here, EPCAM is linked to prostate carcinoma.